| Title |
Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, December 2013
|
| DOI | 10.2147/copd.s52557 |
| Pubmed ID | |
| Authors |
Vamsi Bollu, Frank R Ernst, John Karafilidis, Krithika Rajagopalan, Scott B Robinson, Sidney S Braman |
| Abstract |
Inpatient admissions for chronic obstructive pulmonary disease (COPD) represent a significant economic burden, accounting for over half of direct medical costs. Reducing 30-day readmissions could save health care resources while improving patient care. Recently, the Patient Protection and Affordable Care Act authorized reduced Medicare payments to hospitals with excess readmissions for acute myocardial infarction, heart failure, and pneumonia. Starting in October 2014, hospitals will also be penalized for excess COPD readmissions. This retrospective database study investigated whether use of arformoterol, a nebulized long-acting beta agonist, during an inpatient admission, had different 30-day all-cause readmission rates compared with treatment using nebulized short-acting beta agonists (SABAs, albuterol, or levalbuterol). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 63 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 19% |
| Student > Master | 9 | 14% |
| Other | 8 | 13% |
| Student > Bachelor | 7 | 11% |
| Student > Doctoral Student | 4 | 6% |
| Other | 13 | 21% |
| Unknown | 10 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 41% |
| Nursing and Health Professions | 9 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Economics, Econometrics and Finance | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 11 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2013.
All research outputs
#20,655,488
of 25,371,288 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#2,078
of 2,577 outputs
Outputs of similar age
#245,684
of 320,954 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#21
of 30 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,577 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,954 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.